344 related articles for article (PubMed ID: 19930578)
21. Defining response and non-response to treatment in patients with overactive bladder: a systematic review.
Goldman HB; Wyndaele JJ; Kaplan SA; Wang JT; Ntanios F
Curr Med Res Opin; 2014 Mar; 30(3):509-26. PubMed ID: 24164097
[TBL] [Abstract][Full Text] [Related]
22. Considerations for the management of urgency symptoms in patients with overactive bladder syndrome.
Cardozo LD; Van Kerrebroeck PE; Staskin DR
World J Urol; 2009 Dec; 27(6):755-63. PubMed ID: 19690868
[TBL] [Abstract][Full Text] [Related]
23. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
24. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
25. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
26. Mirabegron for overactive bladder syndrome.
Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
[TBL] [Abstract][Full Text] [Related]
27. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
Haab F
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
[TBL] [Abstract][Full Text] [Related]
28. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
[TBL] [Abstract][Full Text] [Related]
30. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
32. Actual treatment of overactive bladder and urge urinary incontinence.
Cornu JN
Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study.
Bretschneider CE; Liu Q; Smith AR; Kirkali Z; Amundsen CL; Lai H; Geynisman-Tan J; Kirby A; Cameron AP; Helmuth ME; Griffith JW; Jelovsek JE;
Neurourol Urodyn; 2023 Jan; 42(1):194-204. PubMed ID: 36579974
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
Dokmeci F; Cetinkaya SE; Seval MM; Dai O
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
[TBL] [Abstract][Full Text] [Related]
35. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
37. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
[TBL] [Abstract][Full Text] [Related]
38. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
40. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]